Literature DB >> 29770440

Approaches to increase mechanistic understanding and aid in the selection of precipitation inhibitors for supersaturating formulations - a PEARRL review.

Daniel J Price1,2, Felix Ditzinger3,4, Niklas J Koehl5, Sandra Jankovic3,4, Georgia Tsakiridou6,7, Anita Nair1, René Holm8, Martin Kuentz4, Jennifer B Dressman2, Christoph Saal1.   

Abstract

OBJECTIVES: Supersaturating formulations hold great promise for delivery of poorly soluble active pharmaceutical ingredients (APIs). To profit from supersaturating formulations, precipitation is hindered with precipitation inhibitors (PIs), maintaining drug concentrations for as long as possible. This review provides a brief overview of supersaturation and precipitation, focusing on precipitation inhibition. Trial-and-error PI selection will be examined alongside established PI screening techniques. Primarily, however, this review will focus on recent advances that utilise advanced analytical techniques to increase mechanistic understanding of PI action and systematic PI selection. KEY
FINDINGS: Advances in mechanistic understanding have been made possible by the use of analytical tools such as spectroscopy, microscopy and mathematical and molecular modelling, which have been reviewed herein. Using these techniques, PI selection can be guided by molecular rationale. However, more work is required to see widespread application of such an approach for PI selection.
SUMMARY: Precipitation inhibitors are becoming increasingly important in enabling formulations. Trial-and-error approaches have seen success thus far. However, it is essential to learn more about the mode of action of PIs if the most optimal formulations are to be realised. Robust analytical tools, and the knowledge of where and how they can be applied, will be essential in this endeavour.
© 2018 Royal Pharmaceutical Society.

Keywords:  controlled and sustained release systems; development of novel analytical techniques; dosage form design and characterisation; pharmaceutical analysis; pharmaceutics and drug delivery

Mesh:

Substances:

Year:  2018        PMID: 29770440     DOI: 10.1111/jphp.12927

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Classification of the crystallization tendency of active pharmaceutical ingredients (APIs) and nutraceuticals based on their nucleation and crystal growth behaviour in solution state.

Authors:  Sneha Rathi; Rahul B Chavan; Nalini R Shastri
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

Review 2.  A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development.

Authors:  Marilyn N Martinez; Fang Wu; Balint Sinko; David J Brayden; Michael Grass; Filippos Kesisoglou; Aaron Stewart; Kiyohiko Sugano
Journal:  AAPS J       Date:  2022-05-02       Impact factor: 4.009

3.  In Silico, In Vitro, and In Vivo Evaluation of Precipitation Inhibitors in Supersaturated Lipid-Based Formulations of Venetoclax.

Authors:  Niklas J Koehl; Laura J Henze; Harriet Bennett-Lenane; Waleed Faisal; Daniel J Price; René Holm; Martin Kuentz; Brendan T Griffin
Journal:  Mol Pharm       Date:  2021-04-23       Impact factor: 4.939

4.  Opportunities for Successful Stabilization of Poor Glass-Forming Drugs: A Stability-Based Comparison of Mesoporous Silica Versus Hot Melt Extrusion Technologies.

Authors:  Felix Ditzinger; Daniel J Price; Anita Nair; Johanna Becker-Baldus; Clemens Glaubitz; Jennifer B Dressman; Christoph Saal; Martin Kuentz
Journal:  Pharmaceutics       Date:  2019-11-04       Impact factor: 6.321

5.  Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.

Authors:  Pei Liu; Jian-Yu Zhou; Jin-Hua Chang; Xi-Gang Liu; He-Fei Xue; Ru-Xing Wang; Zhong-Si Li; Chun-Shi Li; Jian Wang; Cui-Zhe Liu
Journal:  Drug Des Devel Ther       Date:  2020-07-27       Impact factor: 4.162

6.  A novel architecture for achieving high drug loading in amorphous spray dried dispersion tablets.

Authors:  Deanna M Mudie; Stephanie Buchanan; Aaron M Stewart; Adam Smith; Kimberly B Shepard; Nishant Biswas; Derrick Marshall; Alyssa Ekdahl; Amanda Pluntze; Christopher D Craig; Michael M Morgen; John M Baumann; David T Vodak
Journal:  Int J Pharm X       Date:  2020-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.